Acute myocardial infarction after switching from warfarin to dabigatran

Wael Abuzeid, Hatim Al-Lawati, Neil Fam*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)


Dabigatran etexilate is a recently approved direct thrombin inhibitor (DTI), which is superior to warfarin in the prevention of stroke and systemic embolism in patients with atrial fibrillation (AF). However, dabigatran use is associated with an increased risk of myocardial infarction (MI) compared to warfarin. The mechanisms for this association effect remain speculative. We present a case of an acute MI and cardiac arrest in a patient with chronic AF who had been recently switched from warfarin to dabigatran. Urgent coronary angiography, at St. Michael’s hospital (Toronto, Canada), revealed evidence of thromboembolism to the distal posterior descending artery. The patient was treated medically and switched back from dabigatran to warfarin. He did well and was discharged after an uneventful stay in the coronary care unit.

Original languageEnglish
Pages (from-to)55-58
Number of pages4
JournalOman Medical Journal
Issue number1
Publication statusPublished - 2015
Externally publishedYes


  • Dabigatran
  • Direct thrombin inhibitor
  • Myocardial Infarction
  • Warfarin

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Acute myocardial infarction after switching from warfarin to dabigatran'. Together they form a unique fingerprint.

Cite this